C9 Activators

The chemical class of 'Complement Component 9 (C9) Activators' primarily includes compounds that modulate the complement system, particularly focusing on the components upstream of C9. These chemicals do not directly activate C9 but influence its activation by altering the behavior of preceding components in the complement cascade. The complement system is a crucial part of the immune response, involving a series of small proteins that, upon activation, enhance the abilities of antibodies and phagocytic cells to clear microbes and damaged cells, trigger inflammation, and attack the pathogen's cell membrane.

C9 is the last component in the complement cascade and is involved in forming the membrane attack complex (MAC). Activation of C9 is a critical step in the formation of this complex, which leads to the lysis of target cells. Chemicals like Eculizumab, Nafamostat, and Compstatin act at various points in the complement pathway. For example, Eculizumab inhibits C5, a protein upstream of C9, thereby indirectly affecting the activation of C9. Similarly, Nafamostat, a broad-spectrum serine protease inhibitor, impacts several complement factors that are essential for the eventual activation of C9. Inhibitors of the early stages of the complement pathway, like Conestat alfa and C1 Esterase Inhibitor, potentially regulate the downstream activation of C9 by controlling the initial steps of the cascade.